Fundraising FoxCardioNXT
Westminster, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into CardioNXT
Sign up to see every warm intro you have to CardioNXT
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CardioNXT team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CardioNXT develops cardiac mapping and navigation technology, including its iMap System, used to navigate next-generation pulsed field ablation (PFA) catheters for cardiac procedures such as pulmonary vein isolation and left atrium mapping. The company serves the electrophysiology/cardiac ablation field with features like contact detection and lesion tagging.
Founders & leadership
DC
Donald ContyExecutive
JE
Jerome EdwardsNamed on SEC filing
Board
TK
Thomas KurianBoard director
Investors · 1
Funding
SEC filings, press & company announcements$7M disclosed across 3 rounds · 2016–2019
- $2MraisedJun 2017 · 3 sourcesSource ↗
▶$3MraisedMar 2019 · 3 investors · Other Health CareRule 506(b)
▶$3MraisedMar 2019 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Donald ContyExecutive Officer, Director, Promoter
- Mark D. HackettDirector
- Louise F. BradyDirector
- Jerome EdwardsExecutive Officer, Director, Promoter
- James W. BullockDirector
- Thomas KurianExecutive Officer, Promoter
- Paul KessmanExecutive Officer
- Offering amount
- $4M
- Amount sold
- $3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJun 2017 · 13 investors · Other Health CareRule 506(b)
▶$2MraisedJun 2017 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Donald ContyExecutive Officer, Director, Promoter
- Thomas KurianDirector, Promoter
- Jerome EdwardsExecutive Officer, Director, Promoter
- Offering amount
- $3.5M
- Amount sold
- $2M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AmetrisAmetris provides sensor-based digital measures and digital endpoints for clinical trials, capturing data from wearable sensors and real-world patient insights. Now part of Signant Health, it supports clinical trial sponsors running decentralized, hybrid, and traditional studies alongside electronic Clinical Outcome Assessment (eCOA) capabilities.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Companies working in the same space as CardioNXT.
In the news
Frequently asked questions
- What does CardioNXT do?
- CardioNXT develops cardiac mapping and navigation technology, including its iMap System, used to navigate next-generation pulsed field ablation (PFA) catheters for cardiac procedures such as pulmonary vein isolation and left atrium mapping. The company serves the electrophysiology/cardiac ablation field with features like contact detection and lesion tagging.
- Who are CardioNXT's investors?
- CardioNXT's investors include Solas BioVentures.
- How much funding has CardioNXT raised?
- CardioNXT has disclosed $7M raised across 3 rounds.
- Where is CardioNXT headquartered?
- CardioNXT is headquartered in Westminster, US.